for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MorphoSys AG

MORG.DE

Latest Trade

98.35EUR

Change

-1.60(-1.60%)

Volume

70,195

Today's Range

97.70

 - 

100.50

52 Week Range

76.45

 - 

114.70

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
99.95
Open
100.20
Volume
70,195
3M AVG Volume
2.88
Today's High
100.50
Today's Low
97.70
52 Week High
114.70
52 Week Low
76.45
Shares Out (MIL)
31.67
Market Cap (MIL)
3,191.20
Forward P/E
-32.88
Dividend (Yield %)
--

Next Event

Q3 2019 Morphosys AG Earnings Release

Latest Developments

More

Morphosys: I-Mab Gets IND Clearance For Trials Of TJ202/MOR202

Morphosys Says Janssen Submits FDA Application for Arthritis Drug

Morphosys Sees Higher 2019 Revenues On GSK Milestone Payment

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MorphoSys AG

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The Company develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.

Industry

Biotechnology & Drugs

Contact Info

Semmelweisstr. 7

+49.89.899270

https://www.morphosys.de/

Executive Leadership

Marc Cluzel

Independent Chairman of the Supervisory Board

Jean-Paul Kress

Chief Executive Officer

Frank Morich

Independent Vice Chairman of the Supervisory Board

Jens Holstein

Chief Financial Officer, Member of the Management Board

David Trexler

President - MorphoSys US Inc

Key Stats

2.20 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (EUR)

2016

-2.270

2017

-2.410

2018

-1.792

2019(E)

-3.040
Price To Earnings (TTM)
--
Price To Sales (TTM)
28.06
Price To Book (MRQ)
6.82
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
8.61
LT Debt To Equity (MRQ)
8.16
Return on Investment (TTM)
-8.24
Return on Equity (TTM)
-7.55

Latest News

Latest News

CORRECTED-BRIEF-Morphosys Confirms Higher 2019 Revenue Guidance

* Financial year 2019 guidance, updated in July, confirmed: revenues in range of 65 mln to 72 mln eur

BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study

* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

German biotech group Morphosys seeks European partner for debut drug

German biotech firm Morphosys is in talks with potential partners to bring its debut drug, a therapeutic antibody against leukaemia, to Europe.

Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

BRIEF-Morphosys AG Reports Q1 Revenue Of 2.8 Million EUR

* Q1 REVENUE 2.8 MILLION EUR VERSUS 11.8 MILLION EUR YEAR AGO

BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients

* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS

BRIEF-MorphoSys Announces Approval Of Tremfya(R)In South Korea

* DGAP-NEWS: MORPHOSYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) IN SOUTH KOREA

BRIEF-Morphosys Says NASDAQ IPO Leads To Total Gross Proceeds Of USD 239 Million

* DGAP-NEWS: MORPHOSYS ANNOUNCES CLOSING OF NASDAQ IPO THROUGH AN ADS OFFERING AND EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL ADSS, LEADING TO TOTAL GROSS PROCEEDS OF USD 239 MILLION

BRIEF-Morphosys Announces Pricing Of IPO Of American Depositary Shares On Nasdaq

* MORPHOSYS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES (ADSS) ON NASDAQ

BRIEF-Morphosys to increase capital to implement Offering Of 8.3 mln ADS

* DGAP-ADHOC: MORPHOSYS RESOLVES A CAPITAL INCREASE TO IMPLEMENT THE OFFERING OF 8,300,000 AMERICAN DEPOSITARY SHARES (ADS) IN THE UNITED STATES

BRIEF-Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC Filing

* MORPHOSYS AG SEES U.S. IPO 8.3 MLN AMERICAN DEPOSITARY SHARES - SEC FILING

BRIEF-Morphosys Says Tremfya Approved To Treat Psoriasis In Japan

* SAYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE TO SEVERE FORMS OF PSORIASIS AND PSORIATIC ARTHRITIS IN JAPAN Source text for Eikon: Further company coverage:

BRIEF-Morphosys AG Files For U.S. IPO Of Up To $150 Mln

* MORPHOSYS AG FILES FOR U.S. IPO OF UP TO $150 MILLION – SEC FILING

BRIEF-Morphosys AG Says ‍Files Registration Statement In United States For A Proposed American Depositary Shares (ADS) Offering​

* SAYS FILES REGISTRATION STATEMENT IN UNITED STATES FOR A PROPOSED AMERICAN DEPOSITARY SHARES (ADS) OFFERING

BRIEF-Morphosys Sees EBIT Loss Widening To 110-120 Mln Euros In 2018

* REVENUES 2017 UP 34% TO EUR 66.8 MILLION (GUIDANCE EUR 63 TO 66 MILLION)

BRIEF-Morphosys Announces New Data On Tremfya

* DGAP-NEWS: MORPHOSYS ANNOUNCES THAT TREMFYA(R) (GUSELKUMAB) DATA DEMONSTRATED LONG-TERM SKIN CLEARANCE IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS Source text for Eikon: Further company coverage:

BRIEF-Morphosys And Galapagos Present Results From Phase 1 Study With Mor106

* SAID ON SATURDAY MORPHOSYS AND GALAPAGOS PRESENT RESULTS FROM A PHASE 1 STUDY WITH MOR106 IN ATOPIC DERMATITIS AS LATE-BREAKING ABSTRACT

BRIEF-Galapagos And MorphoSys Present Results From Phase 1 Study With MOR106 In Atopic Dermatitis

* GALAPAGOS AND MORPHOSYS ANNOUNCED ON SATURDAY THAT MOR106 WAS GENERALLY WELL TOLERATED IN ATOPIC DERMATITIS (AD) PATIENTS

BRIEF-Morphosys Presents Clinical Data On MOR208 Plus Lenalidomide In Aggressive Lymphoma

* DGAP-NEWS: MORPHOSYS PRESENTS CLINICAL DATA ON MOR208 PLUS LENALIDOMIDE IN AGGRESSIVE LYMPHOMA (R/R DLBCL) AT ASH 2017 CONFERENCE

BRIEF-Morphosys Says Licensee Janssen Receives Approval For Tremfya In Canada

* DGAP-NEWS: MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS RECEIVED APPROVAL FOR TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up